15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Access, timeliness and retention for HIV testing under early infant diagnosis (EID) program, India

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Early Infant Diagnosis of HIV infection services are crucial for managing the perinatally acquired HIV infection. Assessing the performance of the EID services and its underlying determinants is important for the National AIDS Control Program, India. The objectives of this study were to find out access to HIV testing, the timeliness of the testing cascade, and the proportion of HIV exposed infants who are followed up to 18 months for a definitive diagnosis of HIV. The study design was a mixed method. A total of 11 states accounting for 80% of HIV-positive pregnant women were selected. Program records from a total of 62 Integrated counselling and testing centres (ICTCs) served as the source of information. The qualitative component included interviews of program managers at the state and district level, service providers at the ICTC level, and caregivers of HIV exposed infants. In the sampled 62 ICTCs, 78% of the HIV exposed infants had at least one HIV test. Of the infants who had HIV tests, 50% had at first sample collected by 8 weeks of age. The median turnaround time from sample collection to DNA PCR testing was 36 (IQR 19–70) days and that to next sample collection in case of detection of virus in the first sample was 66 (IQR 55–116) days. At 18 months of age, 544 (62%) HIV exposed infants were retained in the EID testing cascade. A total of 30 infants were diagnosed with HIV at a median age of 421 (IQR 149–650) days. More than three fourth of the HIV exposed infants had access to early infant diagnosis (EID) services. Both demand and supply-side factors contribute to access, timeliness and retention and there is a need to address these factors.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Early antiretroviral therapy and mortality among HIV-infected infants.

          In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial. HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral therapy (lopinavir-ritonavir, zidovudine, and lamivudine) when the CD4 percentage decreased to less than 20% (or 25% if the child was younger than 1 year) or clinical criteria were met (the deferred antiretroviral-therapy group) or to immediate initiation of limited antiretroviral therapy until 1 year of age or 2 years of age (the early antiretroviral-therapy groups). We report the early outcomes for infants who received deferred antiretroviral therapy as compared with early antiretroviral therapy. At a median age of 7.4 weeks (interquartile range, 6.6 to 8.9) and a CD4 percentage of 35.2% (interquartile range, 29.1 to 41.2), 125 infants were randomly assigned to receive deferred therapy, and 252 infants were randomly assigned to receive early therapy. After a median follow-up of 40 weeks (interquartile range, 24 to 58), antiretroviral therapy was initiated in 66% of infants in the deferred-therapy group. Twenty infants in the deferred-therapy group (16%) died versus 10 infants in the early-therapy groups (4%) (hazard ratio for death, 0.24; 95% confidence interval [CI], 0.11 to 0.51; P<0.001). In 32 infants in the deferred-therapy group (26%) versus 16 infants in the early-therapy groups (6%), disease progressed to Centers for Disease Control and Prevention stage C or severe stage B (hazard ratio for disease progression, 0.25; 95% CI, 0.15 to 0.41; P<0.001). Stavudine was substituted for zidovudine in four infants in the early-therapy groups because of neutropenia in three infants and anemia in one infant; no drugs were permanently discontinued. After a review by the data and safety monitoring board, the deferred-therapy group was modified, and infants in this group were all reassessed for initiation of antiretroviral therapy. Early HIV diagnosis and early antiretroviral therapy reduced early infant mortality by 76% and HIV progression by 75%. (ClinicalTrials.gov number, NCT00102960.) 2008 Massachusetts Medical Society
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A systematic review of HIV/AIDS-related stigma and discrimination in India: Current understanding and future needs Translated title: Etude qualitative de la résilience chez des préadolescents orphelins du Sida vivant en institution

            HIV/AIDS-related stigma is recognised as a major barrier to HIV prevention efforts and an impediment to mitigating its impact on individuals and communities. This paper reviews the existing research literature on AIDS stigma in India with the objective of documenting the current status of research, highlighting major findings and identifying key gaps remaining. Thirty publications were identified through a careful search of which a majority focused on stigma assessment and very few on stigma measurement, conceptual aspects of stigma or stigma reduction interventions. A few standardised stigma measures are available but more are required to assess causes of stigma among general population and compounded and internalised stigma among positive people. Research exploring linkages between stigma and HIV services uptake or the effect of HIV care and treatment programs on stigma levels are largely missing and need to be prioritised. In addition, more research is needed to advance conceptual understanding of stigma within the cultural context of the country including research on the neglected groups such as, transgender people. Context-specific (health care, community) interventions are needed to address various forms of stigma – enacted, perceived, internalised and layered – including structural approaches besides inter-personal and information-based approaches. A major gap relates to meager research on developing and evaluating stigma reduction interventions and needs priority focus. Overall, the review recommends developing a national agenda on AIDS stigma research and interventions to help realise the government's goal of stigma reduction. La stigmatisation associée au VIH/Sida est reconnu comme constituant un obstacle majeur aux efforts de prévention du VIH et une difficulté à l'atténuation de son impact sur les individus et les communautés. Cet article passe en revue les articles de recherche existant sur la stigmatisation du Sida en Inde, dans l'objectif de documenter l'état actuel de la recherche, de souligner les conclusions majeures et d'identifier les lacunes essentielles qui subsistent. Trente publications ont été identifiées par une recherche soigneusement conduite, la majorité de ces documents se concentrant sur l'étude de la stigmatisation, très peu portant sur la mesure, les aspects conceptuels ou les interventions de réduction de la stigmatisation. Quelques mesures de stigmatisation standardisées sont disponibles, mais davantage sont nécessaires afin d'évaluer les causes de la stigmatisation dans la population générale et la stigmatisation exacerbée et internalisée par les personnes séropositives. Les travaux de recherche étudiant les liens existant entre la stigmatisation et le recours aux services associés aux VIH ou l'effet des programmes de prise en charge et de traitement du VIH sur les niveaux de stigmatisation sont pour l'essentiel absents et doivent être initiés en priorité. De plus, des travaux de recherche supplémentaires sont nécessaires afin de pouvoir disposer d'une meilleure compréhension conceptuelle de la stigmatisation dans le contexte culturel du pays, et notamment des études sur les groupes négligés tels que les transsexuels. Des interventions spécifiques au contexte (santé, communauté) sont nécessaires afin de pouvoir gérer différentes formes de stigmatisation – affirmée, perçue, internalisée et à plusieurs couches et notamment des approches structurels, en plus des approches interpersonnelles et basées sur les informations. L'une des principales lacunes est constituée par le manque de recherches sur le développement et l'évaluation des interventions de réduction de la stigmatisation et doit être étudiée en priorité. Globalement, l'étude recommande le développement d'un programme national sur la recherche et les interventions en matière de stigmatisation du VIH afin d'aide le gouvernement à atteindre son objectif de réduction de la stigmatisation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency.

               Diagnosis of human immunodeficiency virus (HIV) infection during early infancy (commonly known as "early infant HIV diagnosis" [EID]) followed by prompt initiation of antiretroviral therapy dramatically reduces mortality. EID testing is recommended at 6 weeks of age, but many infant infections are missed.
                Bookmark

                Author and article information

                Contributors
                nilesh.gawde@tiss.edu
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                6 April 2023
                6 April 2023
                2023
                : 13
                : 5638
                Affiliations
                [1 ]GRID grid.419119.5, ISNI 0000 0004 1803 003X, ICMR - National AIDS Research Institute, ; Pune, Maharashtra India
                [2 ]GRID grid.419871.2, ISNI 0000 0004 1937 0757, Tata Institute of Social Sciences, ; Mumbai, Maharashtra India
                [3 ]GMERS Medical College, Sola, Ahmedabad, Gujarat India
                [4 ]Dr. Ram Manohar Lohiya Institute of Medical Sciences, Lucknow, Uttar Pradesh India
                [5 ]GRID grid.417029.9, ISNI 0000 0001 2112 3753, Osmania Medical College, ; Hyderabad, Telangana India
                [6 ]RIMS, Raichur, Karnataka India
                [7 ]GRID grid.412144.6, ISNI 0000 0004 1790 7100, College of Applied Medical Science, , King Khalid University, ; Abha, Kingdom of Saudi Arabia
                [8 ]GRID grid.416267.0, ISNI 0000 0004 1792 1041, Institute of Community Medicine, , Madurai Medical College, ; Madurai, Tamil Nadu India
                [9 ]GRID grid.415282.8, ISNI 0000 0004 1767 3228, SP Medical College, ; Bikaner, Rajasthan India
                [10 ]GRID grid.452679.b, National AIDS Control Organisation, ; New Delhi, India
                Article
                32056
                10.1038/s41598-023-32056-y
                10078073
                37024531
                d8e72ef4-4fd8-4bb0-8dfe-0b99e7f0daa0
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 14 March 2022
                : 21 March 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100008956, National AIDS Control Organisation;
                Award ID: T.11020/98/2014-NACO (R&D)
                Categories
                Article
                Custom metadata
                © The Author(s) 2023

                Uncategorized
                diseases,health care
                Uncategorized
                diseases, health care

                Comments

                Comment on this article